BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Market News

Walmart raises full-year guidance as operating income accelerates to 16 percent in Q3

Moe Alsumidaie by Moe Alsumidaie
November 20, 2026
in Market News
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Walmart’s third-quarter operating income jumped 16.0 percent to $1.1 billion above prior year, driven by margin expansion and eCommerce gains across its core U.S. business. The company raised its full-year fiscal 2027 guidance for both revenue and profit growth, signaling confidence that operational momentum will persist through the final quarter.

Revenue in the quarter reached $188.8 billion, up 5.2 percent, or 4.5 percent in constant currency. Walmart U.S. net sales grew 3.6 percent to $125.0 billion, while Sam’s Club U.S. sales rose 10.0 percent to $25.9 billion. Walmart International net sales increased 7.0 percent to $35.9 billion, though timing of Flipkart’s Big Billion Days sale event created a 500 basis point headwind to that segment’s reported growth.

The company raised its full-year net sales guidance to 4.9 to 5.2 percent growth in constant currency, up from 4.0 to 5.0 percent issued in August. Adjusted operating income guidance rose to 8.0 to 8.6 percent growth, up from 7.0 to 8.5 percent. Adjusted earnings per share for fiscal 2027 is now expected to reach $2.84 to $2.89, compared to $2.64 in fiscal 2026.

What it means

The 16.0 percent operating income growth significantly outpaced the 5.2 percent revenue gain, indicating that Walmart is capturing incremental profit from existing sales rather than relying on volume expansion alone. Gross profit rate improved 28 basis points, led by Walmart U.S., where merchandise category mix and improved business mix drove gains. Walmart U.S. eCommerce sales grew 23 percent, with store-fulfilled pickup and delivery generating most of that lift, a channel that typically carries higher margins than traditional retail. The global advertising business grew 25 percent, with Walmart U.S. advertising up 37 percent, a high-margin revenue stream that expands without requiring additional inventory.

BullScope TerminalYou just read Walmart Inc.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

Operating expense deleverage of 45 basis points at Walmart U.S. tempered margin gains, driven by depreciation expense and higher claims costs. Sam’s Club U.S. operating income fell 15.8 percent to $0.5 billion, weighed by lapping prior-year breakage income from unredeemed rewards and an inflation-related LIFO charge, though the newly launched bundled membership with Walmart+ will continue to pressure that segment’s reported growth until the comparison anniversary arrives in Q3 fiscal 2028.

The guidance raise hinges on whether Walmart U.S. can sustain its 2.9 percent comparable sales growth (excluding fuel) when that figure decelerated from 4.5 percent in the prior year quarter. The company attributes the slowdown partly to deflation in health and wellness from price regulation, a headwind that may persist. Inventory grew 8.1 percent globally to $70.6 billion, outpacing the 5.2 percent revenue growth rate; Walmart attributes this to strategic initiatives, seasonal event timing, and cost inflation. The document does not specify whether inventory growth reflects deliberate stocking ahead of demand or whether excess stock is building. Sam’s Club inventory grew 10.7 percent, though the company notes that excluding fuel, inventory grew in line with sales.

What to watch

Walmart’s fourth-quarter earnings, expected in February 2027, will reveal whether the Flipkart Big Billion Days timing benefit materializes as expected and whether Walmart U.S. comparable sales stabilize above 3 percent. The filing does not disclose the magnitude of the benefit Flipkart’s Q4 timing shift is expected to deliver, leaving the sustainability of the raised guidance partially opaque until that quarter closes.

Source: the company’s 8-K filed 2026-11-19 with the SEC.

BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.

For the standing yardsticks on Walmart: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Walmart.

BullScope TerminalYou just read Walmart Inc.’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Home Depot raises full-year guidance as third-quarter sales accelerate to 4.9 percent

by Moe Alsumidaie
November 18, 2026
0

Home Depot raised its fiscal 2026 sales growth forecast to approximately 4.5 percent, up from an earlier projection, after third-quarter re

Read moreDetails

Disney’s Q4 operating income surges 43% as streaming and parks drive full-year 8% revenue growth

by Moe Alsumidaie
November 18, 2026
0

Disney's fourth quarter operating income jumped 43 percent to $4,970 million, propelled by strength across streaming, sports, and theme par

Read moreDetails

Moderna swings to profit as revenue growth accelerates to 29%, raises full-year outlook to 15-25%

by Moe Alsumidaie
November 9, 2026
0

Moderna reported third-quarter revenue of $1.3 billion, up 29% from $1.0 billion a year earlier, and posted net income of $162 million comp

Read moreDetails

Zoetis narrows revenue outlook as U.S. companion animal sales slide, raises profit guidance on margin strength

by Moe Alsumidaie
November 6, 2026
0

Zoetis cut its full-year revenue forecast to $9.220 billion to $9.320 billion, representing organic operational decline of 2 percent to 1 p

Read moreDetails

Viatris Raises 2026 Guidance as Adjusted EBITDA Climbs 9 Percent Year to Date

by Moe Alsumidaie
November 6, 2026
0

Viatris raised the midpoints of its full-year 2026 financial guidance across all key metrics on the strength of nine-month adjusted EBITDA

Read moreDetails
Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Adobe names Chakravarthy CEO as Narayen steps to executive chair

September 10, 2026

Collegium Pharmaceutical: A Business Growing Into a Price That Has Already Left

September 24, 2026

Evidence Sheet: Chevron (CVX)

November 6, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.